Plain-English translation of NCT05832515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a treatment called autologous hematopoietic stem cell transplantation (AHSCT) combined with two medications — fludarabine and cyclophosphamide — for people with multiple sclerosis (MS) whose disease is worsening despite current treatments. The procedure involves giving you high-dose medications to calm your immune system, then transplanting your own stem cells back into your body to help rebuild a healthier immune system. Researchers hope this treatment will slow or stop disease progression in people with aggressive or advanced MS.
Multiple sclerosis can become severe and stop responding to standard medications, leaving patients with few options. This trial exists because stem cell transplantation has shown promise for some MS patients, but doctors want to find safer medication combinations to reduce serious side effects while keeping the treatment effective.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the two medications (fludarabine and cyclophosphamide) intravenously over several days, followed by additional immune-modifying medications. Your own stem cells will be collected, stored, and then infused back into your body to help restore a healthy immune system. You will need to stay in the hospital during this intensive treatment period and have frequent follow-up visits and blood tests to monitor your safety and how well the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Russia